Morten Graugaard Døssing
Director/Board Member at STipe Therapeutics ApS
Network origin in Morten Graugaard Døssing first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020.
10
| Holding Company | Medical/Nursing Services | 10 |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.
8
| Holding Company | Biotechnology | 8 |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.
6
| Holding Company | Pharmaceuticals: Major | 6 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Morten Graugaard Døssing via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
| ONWARD MEDICAL N.V. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Rigontec GmbH
 Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Director/Board Member Chief Executive Officer | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| COLLEGIUM PHARMACEUTICAL, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
| Perelman School of Medicine | College/University | Doctorate Degree Corporate Officer/Principal | |
| Louisiana State University | College/University | Doctorate Degree Doctorate Degree | |
iOnctura SA
 iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
INKEF Capital BV
 INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor Private Equity Investor | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Founder Director/Board Member | |
| Universität zu Köln | College/University | Doctorate Degree Doctorate Degree | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Chairman Director/Board Member | |
| ARIX BIOSCIENCE PLC | Investment Managers | Corporate Officer/Principal Chief Executive Officer | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member Chairman | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Chief Investment Officer | |
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Corporate Officer/Principal Consultant / Advisor | |
| University of Cambridge | College/University | Graduate Degree Graduate Degree | |
NRG Therapeutics Ltd.
 NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| BICYCLE THERAPEUTICS PLC | Biotechnology | Director/Board Member Corporate Officer/Principal | |
WoB Holding ApS
 WoB Holding ApS Financial ConglomeratesFinance WoB Holding ApS is an investment holding Danish company. The private company is based in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
Bankinvest Biomedical Venture
 Bankinvest Biomedical Venture Investment ManagersFinance Bankinvest Biomedical Venture provides investment services. The company was founded in 1998 and is headquartered in Copenhagen, Denmark. | Investment Managers | Corporate Officer/Principal | |
| University of Liege | College/University | Undergraduate Degree | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Chief Executive Officer | |
EsoBiotec SA
 EsoBiotec SA Miscellaneous Commercial ServicesCommercial Services EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member | |
InnovationsFonden
 InnovationsFonden Investment ManagersFinance InnovationsFonden provides investment services. It invests in entrepreneurs, researchers, and businesses. The company was founded on January 4, 2005 and is headquartered in Copenhagen, Denmark. | Investment Managers | Corporate Officer/Principal | |
Oz Holding ApS
 Oz Holding ApS Financial ConglomeratesFinance Oz Holding ApS provides investment services. | Financial Conglomerates | Director/Board Member | |
Walden Biosciences, Inc.
 Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member | |
| Université Libre de Bruxelles | College/University | Graduate Degree | |
Intomics A/S
 Intomics A/S Miscellaneous Commercial ServicesCommercial Services Intomics A/S provides data analysis solutions to data intensive research projectsa. Its services include advisory service, data analysis, and knowledge management. The firm helps clients in the pharmaceutical industry discover novel and drug targets, identify innovative and discriminative biomarkers, and enhance understanding of the underlying disease-biology at molecular level. The company was founded by Soren Brunak, Kasper Lage, Rasmus Wernersson and Thomas Skot Jensen in 2008 and is headquartered in Kongens Lyngby, Denmark. | Miscellaneous Commercial Services | Director/Board Member | |
Nido Biosciences, Inc.
 Nido Biosciences, Inc. BiotechnologyHealth Technology Nido Biosciences, Inc. focuses on developing small molecule therapeutics for the treatment of neurodegenerative diseases. The company is headquartered in Boston, MA. | Biotechnology | Chief Executive Officer | |
| UCB | Pharmaceuticals: Major | Corporate Officer/Principal | |
Juvenile Diabetes Research Foundation Canada
 Juvenile Diabetes Research Foundation Canada Miscellaneous Commercial ServicesCommercial Services Juvenile Diabetes Research Foundation Canada focuses on type 1 diabetes (T1D) research. The company was founded in 1974 and is headquartered in Toronto, Canada. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
UCB Ventures (Private Equity)
 UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | Investment Managers | Private Equity Investor | |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Medical/Nursing Services | Director/Board Member | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Founder | |
| Licensing Executives Society | Corporate Officer/Principal | ||
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of Aarhus | College/University | Doctorate Degree | |
| Colby College | College/University | Corporate Officer/Principal |
Statistics
International
| United States | 15 |
| Denmark | 13 |
| United Kingdom | 8 |
| Belgium | 6 |
| Switzerland | 5 |
Sectoral
| Health Technology | 19 |
| Consumer Services | 11 |
| Finance | 11 |
| Commercial Services | 10 |
| Health Services | 3 |
Operational
| Director/Board Member | 220 |
| Corporate Officer/Principal | 58 |
| Chief Executive Officer | 41 |
| Chairman | 39 |
| Private Equity Investor | 35 |
Most connected contacts
| Insiders | |
|---|---|
| Regina Hodits | 33 |
| Roel Bulthuis | 29 |
| Sten Verland | 28 |
| Luc Dochez | 26 |
| Michael Heffernan | 23 |
| Fiona MacLaughlin | 22 |
| Henrijette Richter | 21 |
| Jonathan Leslie Tobin | 19 |
| Chris de Souza | 19 |
| Isaac E. Ciechanover | 16 |
| Donald Nicholson | 15 |
| Christina Takke | 14 |
| Anders Hinsby | 14 |
| Jeremy Springhorn | 14 |
| Natalie Sacks | 13 |
- Stock Market
- Insiders
- Morten Graugaard Døssing
- Company connections
